Within 12 months they will have a global multi billion dollar license agreement lined up for cardiovascular indication. There is no drug, no competition in that space and NYR is the only drug in development that has the ability to target these specific receptors. John Moore chairman specifically compared the discovery of TRPC channels to the discovery of GLP-1 receptors for weight loss
Within 12 months on licensing a $3-$4 dollar share price.
3-4 years it would be sold off
NYR Price at posting:
23.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)